Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
This website contains data provided by Euronext. This data is provided "as is" for information purposes only without any guarantees. Although all reasonable precautions have been taken to ensure the accuracy of the data, Euronext does not guarantee accuracy or completeness. Oncodesign cannot be held responsible for the use of these data. This information cannot be considered as creating rights or commitments from Oncodesign or any representative company.
A true entrepreneurial project and a rare occurrence in biotechnology, Oncodesign’s capital is mainly held by its managers, including Dr. Philippe Genne, CEO and Founder of the company. The interests of management and shareholders remain perfectly aligned.